| scholarly article | Q13442814 |
| P50 | author | Joan Massagué Solé | Q462775 |
| Stephen B. Baylin | Q28113000 | ||
| Linda T Vahdat | Q40149511 | ||
| Sevin Turcan | Q42574772 | ||
| Andreas Rimner | Q52313562 | ||
| Mary Ellen Moynahan | Q57518016 | ||
| Venkatraman E Seshan | Q104745215 | ||
| Larry Norton | Q37644083 | ||
| P2093 | author name string | Fang Fang | |
| Ronglai Shen | |||
| Adriana Heguy | |||
| Timothy A Chan | |||
| Qianxing Mo | |||
| Agnes Viale | |||
| Nita Ahuja | |||
| Andrew Kaufman | |||
| Luc G T Morris | |||
| Dilip Giri | |||
| P2860 | cites work | Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains | Q21092474 |
| BRCA1 affects global DNA methylation through regulation of DNMT1 | Q24298913 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry | Q24536837 | ||
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| DAVID: Database for Annotation, Visualization, and Integrated Discovery | Q27499374 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Worms gang up on bacteria | Q27860588 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| The consensus coding sequences of human breast and colorectal cancers | Q27861035 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| DNMT1 and DNMT3b cooperate to silence genes in human cancer cells | Q28212826 | ||
| Control of developmental regulators by Polycomb in human embryonic stem cells | Q28235841 | ||
| PIK3CA mutation associates with improved outcome in breast cancer. | Q38420422 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Smad signaling is required to maintain epigenetic silencing during breast cancer progression. | Q39750283 | ||
| DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients | Q40060957 | ||
| Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells | Q40088678 | ||
| Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. | Q44124289 | ||
| The fundamental role of epigenetic events in cancer | Q56421597 | ||
| Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis | Q57240066 | ||
| Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer | Q59565565 | ||
| Gene-expression profiles in hereditary breast cancer | Q74111111 | ||
| Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors | Q79175646 | ||
| Hypermethylation in histologically distinct classes of breast cancer | Q80787663 | ||
| Colon cancer: it's CIN or CIMP | Q82175754 | ||
| The epigenomics of cancer | Q28289975 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Genome remodelling in a basal-like breast cancer metastasis and xenograft | Q28395637 | ||
| Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis | Q28472991 | ||
| PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes | Q29547229 | ||
| Genes that mediate breast cancer metastasis to lung | Q29547479 | ||
| GenePattern 2.0 | Q29614171 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions | Q29614512 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| Hypomethylation distinguishes genes of some human cancers from their normal counterparts | Q29619217 | ||
| Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer | Q29622925 | ||
| A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing | Q33268624 | ||
| Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients | Q33540332 | ||
| Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. | Q33649722 | ||
| LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer | Q33848195 | ||
| Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. | Q33888431 | ||
| Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer | Q34018681 | ||
| Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. | Q34477787 | ||
| Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors | Q34573834 | ||
| DNA methylation markers and early recurrence in stage I lung cancer | Q34761286 | ||
| Basal-like breast cancer displays distinct patterns of promoter methylation | Q34982503 | ||
| DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations | Q35009790 | ||
| Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer | Q35605804 | ||
| Lung metastasis genes couple breast tumor size and metastatic spread. | Q35800363 | ||
| Molecular concepts analysis links tumors, pathways, mechanisms, and drugs | Q35812701 | ||
| High-throughput methylation profiling by MCA coupled to CpG island microarray | Q36004673 | ||
| Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer | Q36059237 | ||
| DNA methylation profiles of female steroid hormone-driven human malignancies. | Q36566168 | ||
| Genetic determinants of cancer metastasis | Q36794312 | ||
| The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer | Q37131378 | ||
| Bisulfite-based epityping on pooled genomic DNA provides an accurate estimate of average group DNA methylation | Q37133978 | ||
| Agglomerative epigenetic aberrations are a common event in human breast cancer | Q37187180 | ||
| DNA methylation as a biomarker in breast cancer | Q37620392 | ||
| P433 | issue | 75 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 75ra25 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Breast cancer methylomes establish an epigenomic foundation for metastasis | |
| P478 | volume | 3 |
| Q90470157 | 5-Aza-2'-deoxycytidine advances EMT of breast cancer cells by demethylating Sipa1 promoter-proximal elements |
| Q89900894 | 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming |
| Q39028173 | A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. |
| Q35914847 | A DNA hypermethylation module for the stem/progenitor cell signature of cancer. |
| Q41135908 | A DNA methylation-based definition of biologically distinct breast cancer subtypes |
| Q36545127 | A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness. |
| Q38403894 | A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia |
| Q36446183 | A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. |
| Q38771093 | A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer |
| Q37582122 | Aberrant promoter methylation of cancer-related genes in human breast cancer |
| Q37655854 | Age-related DNA methylation in normal breast tissue and its relationship with invasive breast tumor methylation. |
| Q37706140 | An annotated list of bivalent chromatin regions in human ES cells: a new tool for cancer epigenetic research |
| Q46324231 | Analysis of Tumor Biology to Advance Cancer Health Disparity Research. |
| Q57113927 | Applications of RNA Indexes for Precision Oncology in Breast Cancer |
| Q41274606 | BRCA2 carriers with male breast cancer show elevated tumour methylation |
| Q39414264 | Bone morphogenetic protein (BMP) signaling regulates mitotic checkpoint protein levels in human breast cancer cells |
| Q33920767 | Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. |
| Q34533607 | Cell-type specific DNA methylation patterns define human breast cellular identity |
| Q37410593 | Characterizing DNA methylation alterations from The Cancer Genome Atlas |
| Q33797074 | Clinical Genomics: Challenges and Opportunities |
| Q34743908 | Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge. |
| Q27025145 | Common gene pathways and families altered by DNA methylation in breast and prostate cancers |
| Q38815614 | Comparative DNA methylation analysis to decipher common and cell type-specific patterns among multiple cell types |
| Q48098943 | Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer |
| Q34310031 | Conventional and Nanotechniques for DNA Methylation Profiling |
| Q36351328 | CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. |
| Q84078513 | DNA Methylation As a Clinical Marker in Oncology |
| Q91838904 | DNA Methylation Markers for Breast Cancer Detection in the Developing World |
| Q83498596 | DNA Methylation and Histone Modifications in Breast Cancer |
| Q39208639 | DNA methylation aberrancies as a guide for surveillance and treatment of human cancers |
| Q36187834 | DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status |
| Q36583742 | DNA methylation and hormone receptor status in breast cancer |
| Q36768855 | DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification |
| Q27690722 | DNA methylation changes in epithelial ovarian cancer histotypes |
| Q35888926 | DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer |
| Q39983760 | DNA methylation plasticity contributes to the natural history of metastasis |
| Q35667377 | DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses |
| Q35000317 | DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival |
| Q38040319 | DNA methylation profiling in the clinic: applications and challenges |
| Q36038847 | DNA methylation profiling reveals a predominant immune component in breast cancers. |
| Q36245189 | DNA methylation signatures for breast cancer classification and prognosis |
| Q33617129 | DNA methylation: potential biomarker in Hepatocellular Carcinoma. |
| Q89518530 | DNA sequence context as a marker of CpG methylation instability in normal and cancer tissues |
| Q40040077 | Deconvolution of DNA methylation identifies differentially methylated gene regions on 1p36 across breast cancer subtypes. |
| Q35631191 | DiseaseMeth: a human disease methylation database |
| Q28542556 | Do breast cancer cell lines provide a relevant model of the patient tumor methylome? |
| Q36757298 | Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers |
| Q89836150 | Effect of early parenteral nutrition during paediatric critical illness on DNA methylation as a potential mediator of impaired neurocognitive development: a pre-planned secondary analysis of the PEPaNIC international randomised controlled trial |
| Q34000392 | Effect of estrogen receptor α binding on functional DNA methylation in breast cancer |
| Q84699545 | Epigenetic Biomarkers |
| Q92702483 | Epigenetic Dysregulation at the Crossroad of Women's Cancer |
| Q42367979 | Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer |
| Q37142504 | Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR |
| Q35835175 | Epigenetic activities of flavonoids in the prevention and treatment of cancer |
| Q52332848 | Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer |
| Q37962606 | Epigenetic and Epigenomic Mechanisms Shape Sarcoma and Other Mesenchymal Tumor Pathogenesis |
| Q36957014 | Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma |
| Q33740709 | Epigenetic deregulation in pediatric acute lymphoblastic leukemia. |
| Q28079377 | Epigenetic determinants of metastasis |
| Q39388476 | Epigenetic disruption of cadherin-11 in human cancer metastasis. |
| Q38213062 | Epigenetic dysregulation in glioma. |
| Q38296760 | Epigenetic mechanisms of breast cancer: an update of the current knowledge |
| Q36212916 | Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer. |
| Q41093581 | Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. |
| Q36738463 | Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management |
| Q36245180 | Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation |
| Q50020927 | Epigenetics and Precision Oncology |
| Q26991779 | Epigenetics in breast cancer: what's new? |
| Q92917105 | Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q57265567 | Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer |
| Q34240198 | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy |
| Q26830534 | Epigenomics of cancer - emerging new concepts |
| Q39752527 | Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code |
| Q26852086 | Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role |
| Q52714523 | Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer. |
| Q37709387 | Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer. |
| Q36446270 | Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies |
| Q35841605 | Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence |
| Q39430136 | Genome-wide methylation analysis of DNMT3B gene isoforms revealed specific methylation profiles in breast cell lines |
| Q35035170 | Genome-wide promoter methylome of small renal masses |
| Q34964303 | Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer |
| Q34647477 | Genomic insights into cancer-associated aberrant CpG island hypermethylation |
| Q38175087 | Harnessing the potential of epigenetic therapy to target solid tumors. |
| Q47247432 | Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes |
| Q29617457 | IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype |
| Q64937859 | ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. |
| Q34590776 | Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma |
| Q28741689 | Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer |
| Q36302529 | Identification of endometrial cancer methylation features using combined methylation analysis methods |
| Q47448556 | Identification of key genes in glioma CpG island methylator phenotype via network analysis of gene expression data |
| Q37076838 | Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles |
| Q30910707 | Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients |
| Q44582365 | Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma |
| Q37224735 | Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer |
| Q26782613 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential |
| Q36154630 | Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype |
| Q47960568 | Interethnic DNA methylation difference and its implications in pharmacoepigenetics |
| Q38019416 | Intratumoral stages of metastatic cells: A synthesis of ontogeny, Rho/Rac GTPases, epithelial‐mesenchymal transitions, and more |
| Q36910353 | Luminal B breast cancer subtype displays a dicotomic epigenetic pattern |
| Q34004837 | Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis |
| Q35000210 | Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features |
| Q90024184 | Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer |
| Q38388111 | Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. |
| Q33810504 | Micro- and nanoscale devices for the investigation of epigenetics and chromatin dynamics |
| Q93108431 | MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer |
| Q47142132 | MicroRNA in Glioblastoma: An Overview |
| Q132045716 | Molecular Mechanisms of Breast Cancer Metastasis |
| Q60919172 | Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours |
| Q24289344 | Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease |
| Q24610836 | Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas |
| Q64073594 | NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients |
| Q36280804 | Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers |
| Q38282894 | Pan-cancer patterns of DNA methylation. |
| Q35583813 | Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype |
| Q64114346 | Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation |
| Q37696099 | Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity |
| Q39012550 | Pharmacoepigenetics: an element of personalized therapy? |
| Q28393302 | Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis |
| Q89471843 | Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review |
| Q36746247 | Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma |
| Q46950071 | Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis |
| Q45072707 | Readers of DNA methylation, the MBD family as potential therapeutic targets. |
| Q34100927 | Reduced ING1 levels in breast cancer promotes metastasis |
| Q33989254 | Remodeling of the methylation landscape in breast cancer metastasis. |
| Q35963443 | Role of epigenetic modifications in luminal breast cancer |
| Q37946239 | Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome: An Overview |
| Q34626018 | Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients |
| Q38015229 | Strategies for the discovery and development of therapies for metastatic breast cancer |
| Q38834039 | Survival differences of CIMP subtypes integrated with CNA information in human breast cancer |
| Q89068430 | TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer |
| Q90012107 | TROP2 methylation and expression in tamoxifen-resistant breast cancer |
| Q53201323 | Targeting the epigenome for treatment of cancer |
| Q38944944 | The CpG island methylator phenotype in breast cancer is associated with the lobular subtype |
| Q28075374 | The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation |
| Q37645687 | The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming |
| Q52966734 | The Role of DNA Methylation in Cancer |
| Q34499855 | The molecular genomics of metastatic brain tumours. |
| Q38306663 | Therapeutic targeting of tumor suppressor genes |
| Q36378085 | Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns |
| Q90167366 | Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms |
| Q37938532 | Unravelling the epigenomic dimension of breast cancers |
| Q60529799 | Validation of DNA promoter hypermethylation biomarkers in breast cancer — a short report |
| Q36194281 | eFORGE: A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data |
Search more.